Brian L. Kotzin
Independent DirectorDr. Brian L. Kotzin, M.D. is Director of Genascence Corporation from May 2022. Dr. Kotzin served as Interim Chief Medical Officer of Nektar Therapeutics since February 04, 2025 until September 2025. He was Independent Director of Rigel Pharmaceuticals, Inc. from August 2017 to September 16, 2024. He is Non-Executive Director of argenx SE from May 7, 2024. Dr. Kotzin has broad medical and scientific research and development experience. Dr. Kotzin serves as Member of Scientific Advisory Board at Human Immunology Biosciences, Inc. He has been Head of Clinical Development for Nektar’s immunology program since April 2017. Dr. Kotzin has served as Chief Executive Officer of BL Kotzin, Inc., a consulting services company, since 2015. He served as Chief Medical Officer at Nektar Therapeutics since April 2022 until June 2023. He served as Senior Vice President at Nektar Therapeutics since April 2022 until 2022. He had been an Interim Chief Medical Officer of Nektar Therapeutics from January 5, 2021 to July 2021 and served as its Senior Vice President of Clinical Development since April 2017 until June 2023 and served as Head of Immunology of Nektar Therapeutics since May 03, 2017 until June 2023. Dr. Kotzin leads clinical development for NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders. During his employment at Amgen Inc. he also served as Vice President, Translational Sciences and Head of Medical Sciences from February 2006 to July 2011. Dr. Kotzin was a faculty member in the Division of Rheumatology of the Department of Medicine and Department of Immunology at the University of Colorado Health Sciences Center in Denver, Colorado from September 1981 to July 2004. He serves as the Member of Board Directors at Genascence Corporation since May 2022. Dr. Kotzin is a highly respected clinical researcher with an outstanding reputation and expertise in inflammation and immunology. He had been Member of Scientific & Clinical Advisory Board at Equillium, Inc since May 6, 2019 until November 2023. Dr. Kotzin served as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area of Amgen Inc. from July 12, 2004 to January 2015 and served as Head of Medical Sciences. Dr. Kotzin directs the global development efforts for all new Amgen product candidates in the inflammation area. During his time at Amgen, he also served as Vice President of Medical Sciences. He has drug development experience and he is an expert in the areas of immunology and inflammatory diseases. Dr. Kotzin joined Amgen from the University of Colorado Health Sciences Center in Denver, where he served as Head of Clinical Immunology in the Department of Medicine and director of the Autoimmunity Center of Excellence from July 1998 to July 2004. He held the position of Professor in the Departments of Medicine, Pediatrics and Immunology at the National Jewish Medical and Research Center in Denver. Dr. Kotzin served at the Veterans Administration Medical Center in Denver as chief of the Rheumatology Section. He serves as a Member of Scientific Advisory Board at Terray Therapeutics, Inc. He serves as Scientific Advisor at Q32 Bio Inc. Dr. Kotzin served as a Member of Scientific Advisory Board at Biocon Limited. He has been Independent Director of Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since June 2019. He serves as a Member of the Board of Directors at Federation of Clinical Immunology Societies (FOCIS). Dr. Kotzin served as Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence. Dr. Kotzin was appointed to the Advisory Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health. He has published extensively and served on the editorial boards of Arthritis and Rheumatism, The Journal of Immunology and the Journal of Clinical Investigation. He is an Associate Editor at Clinical Investigation. He is board certified in rheumatology and internal medicine. A board-certified rheumatologist and internist, Dr. Kotzin is Principal Fellow, Clinical Development at Nektar Therapeutics. He was Director of Vera Therapeutics, Incorporated since 2020. He had been an Independent Director of Kyverna Therapeutics, Inc. since August 2019 until September 2024. He is an elected member of the American Association of Clinical Investigation and the Association of American Physicians. He serves as Chairman of Scientific Advisory Board of Aristea Therapeutics, Inc. Dr. Kotzin has won numerous honors, including elected Master of the American College of Rheumatology, the Kirkland Scholar Award for Lupus Research, the Henry Claman Chair in Clinical Immunology, the Gretchen Kramer Award for Outstanding Contributions to Medicine and Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence. He holds Post-Doctoral Fellowship in Immunology & Rheumatology from Stanford University. Dr. Kotzin earned his M.D. from Stanford University and his B.S. in Mathematics from the University of Southern California.
Positions
- Company NameBiora Therapeutics, Inc.Stock CodeBIORQPositionIndependent DirectorColleagues
- APAditya P. MohantyCEO & Director
- JDJeffrey Donald AlterIndependent Chairman
- CNClarke NeumannSenior VP, General Counsel & Secretary
- KHKevin HoweSenior VP of Strategic Operations
- PSPaul ShabramHead of Technical Operations
- JKJames KnightHead of Business Development
- BEBruce E. SandsChairman of Inflammatory Bowel Disease Clinical Advisory Board
- JAJill Ann HoweIndependent Director
